Tranquis Therapeutics Launches with $30 Million Series A Funding to Advance Novel Immuno-Neurology Approach to Treating Neurodegenerative and Aging-related Diseases

- Platform based on groundbreaking research from the laboratory of Professor Edgar Engleman, MD, at Stanford University indicating that myeloid immune cell dysfunction underlies a variety of nervous system disorders -

- Initial development focused in orphan diseases such as Amyotrophic Lateral Sclerosis and Frontotemporal Dementia, with planned expansion into more prevalent diseases such as Parkinson’s and Alzheimer’s -

SAN MATEO, Calif., July 9, 2020-- Tranquis Therapeutics, a private immuno-neurology company, launched today with $30 million in Series A funding …